Form 4: Collegium Pharma EVP Sells Shares
Insider Transaction Report
Collegium Pharmaceutical's EVP & Chief Commercial Officer, Scott Dreyer, exercised stock options and sold an equal number of shares under a pre-arranged 10b5-1 trading plan.
Summary
- Scott Dreyer, EVP & Chief Commercial Officer of Collegium Pharmaceutical, Inc. (COLL), engaged in two transactions on August 18, 2025.
- He exercised stock options to acquire 16,389 shares of common stock at an exercise price of $21.34 per share.
- Immediately following the exercise, he sold 16,389 shares of common stock at a weighted average price of $38.2068 per share, with prices ranging from $38.00 to $38.465.
- These transactions were conducted pursuant to a Rule 10b5-1 trading plan adopted on August 28, 2024.
- Following these transactions, Mr. Dreyer beneficially owns 103,613 shares of Collegium Pharmaceutical common stock.
Sentiment
Score: 5
Explanation: The sentiment is neutral. While an insider sale can be perceived negatively, the fact that it was conducted under a pre-arranged 10b5-1 plan mitigates concerns about opportunistic selling. It represents a routine liquidity event for an executive.
Positives
- The exercise of stock options indicates a prior grant of equity compensation, aligning executive incentives with shareholder value.
- The transactions were executed under a pre-arranged Rule 10b5-1 trading plan, which provides an affirmative defense against insider trading allegations.
Negatives
- The sale of shares by a key executive, even under a 10b5-1 plan, reduces their direct ownership stake in the company.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Power of Attorney Grant | Scott Dreyer granted a Power of Attorney to Vikram Karnani, Colleen Tupper, and David Dieter to execute and file SEC Forms 3, 4, and 5 on his behalf. | 2025-08-15 | Streamlines the process for executive SEC filings, ensuring timely compliance with reporting obligations. |
Stakeholder Impact
- Shareholders: The sale of shares by a key executive could be interpreted differently by investors; however, the 10b5-1 plan suggests a pre-planned liquidity event rather than a reaction to new negative information.
Key Dates
| Date | Description |
|---|---|
| 2024-08-28 | Date Rule 10b5-1 trading plan was adopted by Scott Dreyer. |
| 2025-08-15 | Effective date of the Power of Attorney granted by Scott Dreyer. |
| 2025-08-18 | Date of stock option exercise and subsequent sale of common stock by Scott Dreyer. |
| 2025-08-20 | Date the Form 4 was signed by Colleen Tupper as Attorney-In-Fact for Scott Dreyer. |
| 2030-02-05 | Expiration date of the exercised stock option. |
Recommendation
holdThe filing details a routine insider transaction (exercise and sale) executed under a pre-arranged 10b5-1 plan. This type of transaction is generally not indicative of a change in the company's fundamental outlook or a signal for immediate investment action. It's a liquidity event for the executive and does not provide new information to warrant a 'buy' or 'sell' recommendation based solely on this filing.
Keywords
Collegium Pharmaceutical, COLL, Scott Dreyer, Form 4, Insider Trading, Stock Option Exercise, Share Sale, 10b5-1 Plan, Executive Compensation, Pharmaceuticals
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.